Jason Amello
CIK 1451805 · Chief Financial Officer · last filed 2026-01-22
Jason Amello is a Chief Financial Officer who has filed 35 SEC Form 4 insider transactions across 7 companies since 2009. The most recent filing, for TCRX, was dated Jan 22, 2026. Across all open-market trades the lifetime net is −$460.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.86M
7
35
-$460.6K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TCRX | Chief Financial Officer | — | $0.91 | — | $0 | 3 | 2026-01-22 |
| CADL | Chief Financial Officer | 202,009 | $8.56 | $1.73M | $10.0K | 6 | 2023-11-30 |
| Acer Therapeutics Inc. (ACER) Delisted | Director | — | $0.66 | — | $0 | 5 | 2023-03-16 |
| AKBA | SVP, CFO & Treasurer | 144,642 | $0.92 | $133.7K | $20.5K | 11 | 2020-03-02 |
| Acer Therapeutics Inc. (ACERW) Delisted | Director | — | — | — | $0 | 1 | 2017-10-06 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Executive Vice President & CFO | 22,377 | $0.87 | $19.4K | $0 | 4 | 2013-05-14 |
| GENZYME CORP (GENZ) Delisted | CorpContrllr,ChiefAccntOfficer | 5,005 | — | — | -$491.1K | 5 | 2011-04-06 |
Recent Filings
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-22 | TCRX | Grant (A) | — | $0 | EDGAR |
| 2025-02-11 | TCRX | Grant (A) | — | $0 | EDGAR |
| 2024-02-02 | TCRX | Grant (A) | — | $0 | EDGAR |
| 2023-11-30 | CADL | Tax (F) | −20,153 | -$18.1K | EDGAR |
| 2023-11-28 | CADL | Grant (A) | +125,717 | $0 | EDGAR |
| 2023-05-02 | CADL | Grant (A) | — | $0 | EDGAR |
| 2023-03-16 | Acer Therapeutics Inc. (ACER) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-12-12 | CADL | Buy (P) | +5,568 | $10.0K | EDGAR |
| 2022-11-30 | CADL | Grant (A) | +90,877 | $0 | EDGAR |
| 2022-09-23 | CADL | Grant (A) | — | $0 | EDGAR |